The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah great update, revenue, cash, profit all up with EBITDA hitting at least (Read exceeding?) expectations!
Despite this uncertainty in the clinical trials market, the Company confirms its outlook for the 2021 financial year, reflecting its strong order book of future revenues and robust balance sheet.
Agreed, I'm still relatively new to the investing scene (since 2016) and have really learned the value of patience when you find these hidden gems. Originally I was after big gains within a few weeks, and would sell out due to limited price movement, but in most instances the firm just keeps building and eventually it will be picked up by someone like Simon Thompson (IC), SCSW and then it rockets. I know they're not the same but just look at Ergomed since SCSW has been tipping them
richtips i totally agree with you comments , I have been a shareholder since REVERSE TAKEOVER OF PHYTOPHARM, They have come a long way since then well run well funded and respected in the industry . They will move when they next have a major contract win meanwhile they are fair value.
Just bought in this week after having spent a lot of time researching over the weekend. Really like the look of the company and shares many similarities to VLG when I first bought in in the 30s.
Edging into profitability, low shares in issue, high number in II / BOD hands (63% ish), relatively under the radar.
May not see significant growth in share price for a while but more of these “ahead of expectations” comments.... when it comes it will rocket
Sorry orderbook for FY 2021 I meant below
Hats off to them and great company. What I'm mystified about is that the CEO + CFO has already mentioned on a number of times in the most recent investors' presentation that the company will be "consolidating", increasing capex. The CEO further mentioned that the orderbook, given big pharmas' attention is away from their usual drug trials, will not be as large as this FY (or words to that extent).
This indicates that the late buyers of the share on Thurs + Fri must have super confidence in the long term when the FY 2021 is expected to be somewhat subdued due to C19 impacting on the order books. Of course, this does not mean that the future is not bright, since the CEO did mention the orders would be pushed back later into FY 2022.
Uptick in SP this afternoon will be due to RNS at 11.55am today from Ixico on yesterday's Investor presentation
"IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.
"Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: https://www.investormeetcompany.com/ixico-plc/register-investor
No new price-sensitive information is disclosed as part of the presentation."
Proactive interview on Monday with Giulio Cerroni “after announcing they've raised earnings expectations for the current fiscal year.”
“He says revenues for the year to the end of September 2020 will be in line with, or slightly ahead of, current market expectations, representing growth of more than 20% compared to the prior year.”
“Underlying earnings are expected to be materially ahead of current market expectations.”
Nothing very much new added to the great RNS but a reassuring interview with Giulio.
https://www.youtube.com/watch?v=4LXS7fQ1yzQ or Giulio's interview can be played direct from the Ixico web site. Go to Investors, Investors Info, Investors Videos
IXICO shares are very limited on the market ,it is very hard to buy big volumes.
Average volume 55.69k
Shares outstanding 47.09m
Free float 28.18m
P/E (TTM) 47.26
Market cap 32.49m GBP
EPS (TTM) 0.0146 GB
85p on the ask already so 1st target/resistance level reached even quicker than I expected!
Live price is 83-85p (+22%)
We might see a bit of up and down and a few games at this level but I'm holding out for a test of the 52-week high of 96p over the next few days/weeks.
I haven't been able to buy any in my ISA as it took ages to sell my last few 7DIG shares and can't get a price to buy at the moment but that may be more to do with Share Centre than the availability of stock. Is anyone following Level 2 on this or able to do dummy trades?
Looks to be gaining some momentum now.
Live price 81-82p (+18%)
I hadn't previously heard of IXICO but I spotted the RNS this morning and after doing some initial research I opened a long bet on Spreadex at the open for 73.2p
Having done some more digging since, there is so much to be excited about here!
- Double digit revenue growth (20%+) 4 years in a row
- Increasingly profitable revenue growth with EBITDA "materially ahead of current market expectations"
- Debt-free
- Strong cash position
- Very strong trade receivables profile from servicing well funded global pharmaceuticals industry
- Low number of shares in issue (c.47mil)
- Very strong Institutional Investor support with over 66% of shares held by 5 funds each holding 10%+
- Currently not on the radar of most Private Investors hence the quiet board here and the subdued shareprice
- Sealed largest ever contract worth over £10mil in April 2020 despite Covid-19 pandemic
I'm yet to find any reasons not to be positive about this company and as always I am trying! Once I've freed up some funds (hopefully from selling my remaining 7DIG shares at a decent price) I will be looking to build a position here.
From a quick glance at the charts it looks like resistance around 75p is key with next targets at c.85p and then the 52 week high at 96p.
Current price is 76-77p (+10.9%)
24 August 2020
IXICO plc
("IXICO" or the "Company")
Trading Update
Profitability for full year 2020 expected to be ahead of market expectations
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that, despite COVID-19, it is achieving stronger than anticipated growth across the second half of the year. The Company is benefiting from continued operational leverage, generated by revenue growth and investments made to drive scale and efficiency.
Given the performance in the period to date, the Board expects revenues for the full year to 30 September 2020 to be in line with, or slightly ahead of, current market expectations, representing growth of more than 20% compared to the prior year. Further, the Board anticipates that earnings before interest, tax, depreciation, and amortisation (EBITDA) will be materially ahead of current market expectations.
This enhancement of financial performance expectations for FY20 further underpins the Company's confidence in its ability to invest to deliver further profitable medium and long-term growth.
As previously announced, IXICO will be presenting on Tuesday 25 August at 1.30pm. The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link: https://www.investormeetcompany.com/ixico-plc/register-investor.
Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are delighted to see continued momentum in the accessing of revenue driven operational leverage, building on the Company's maiden year of profitability in 2019 and strong first half year results to 31 March 2020. In the context of the challenging market environment created by Covid-19, this increase in profitable growth, alongside our strong balance sheet and positive operating cashflows, whilst remaining fully committed to our investment plans, is a fantastic achievement."
Very positive update this will get share price moving market indication +10%
Covid slowed growth down for awhile share price weaken of fears of lose of orders due to covid
Thanks for keeping this board up and running old trader where do you see the share price on good news? I recall you saying we should be over 100 already but can’t recall why
Bought stock before presentation next week They have drifted with lack of news Cheap IMO
Took advantage of the pullback today and doubled my position
https://www.youtube.com/watch?v=GJfpfgTsl3g
"IXICO PLC's CEO Giulio Cerroni tells Proactive's Andrew Scott the impact of the coronavirus pandemic has been modest on its business and he's expecting to see double-digit revenue growth this year and next.
"Cerroni says he's confident of generating at least £9.1mln of revenue for the year to 30 September 2020, with £0.9mln in underlying profit and positive operating cash."
IMHO: The future is bright, the future is IXICO!
They are doing very well .Rember in March they won a £10.5 M new contract CEO did say he expected to see some slowdown because of Covid they will go over 100 before year is out . Ixico is a very exciting company well run with very loyal staff
Speaking of high price mark old trader what happened to the roughly 90.00 we had last year? I was under the impression business for Ixico was going better since then not worse so not sure what happened since then.